Spironolactone to Decrease Potassium Wasting in Hypercalciurics on Thiazides Diuretics

See rationale above

Ten patients who have had multiple kidney stones primarily due to hypercalciuria and who are currently on stable dose of thiazide or thiazide plus amiloride will be enrolled in the study. In addition, pts have to require at least 60mEq of K supplementation a day or be on 40mEq and be hypokalemic and unable to tolerate increased K supplements. We will then give them 50mg a day of spironolactone for four weeks. A complete 24-hour urine stone profile will be obtained before and after the drug is administered. After four weeks the patients' serum potassium will be rechecked, and their dose will be lowered according to a nomogram.

Primary end point is the mean change in serum K before and after spironolactone. Secondary endpoints are the change in urine calcium on and off the drug and the mean reduction in K dose on the drug.

Inclusion criteria

• Age 18-65
• History of idiopathic hypercalciuria (>200mg per 24 hours or a Ca/cr ratio of >140) felt to be the primary etiology of patient's kidney stones
• History of at least three kidney stone events
• On same dose of thiazide diuretic for at least three months
• On stable dose of K 60mEq or more a day to maintain serum K >3.5 or unable to tolerate an increase in K supplement with dose at least 40mEq a day

Exclusion criteria

• Use of ACE inhibitor, ACE receptor blocker or other medication known to effect serum potassium levels
• GFR <80 by MDRD equation
• Serious cardiac disease, diabetes, CKD , current or planned pregnancy or breastfeeding
• History of hypertension